FindTrial
Sign In

Neuromuscular blocking properties of cisatracurium: A comparative study in breast cancer patients with or without neoadjuvant chemotherapy

Neuromuscular blocking properties of cisatracurium: A comparative study in breast cancer patients with or without neoadjuvant chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017027
Enrollment
100
Registered
2019-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Breast cancer Health Condition 2: C50- Malignant neoplasm of breast

Interventions

None listed

Sponsors

Rajiv Gandhi Cancer Institute and Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I/II patients with breast cancer aged -70 years who received neoadjuvant chemotherapy within 30 days prior to surgery

Exclusion criteria

Exclusion criteria: patient refusal patient with neuromuscular disorder patient taking aminoglycoside/ tetracycline antibiotic anticipated difficult intubation patient requiring rapid sequence induction

Design outcomes

Primary

MeasureTime frame
compare effect of cistracurium in terms of ST0, PTC1,TOF1 and TOF4Timepoint: 1. disappearance of single twitch after initial bolus 2.appearance of 1st PTC and TOF after initial bolus dose and 3. appearance of fourth TOF after last top up dose—

Secondary

MeasureTime frame
correlate preop magnesium levels with st0,ptc1, tof 1, tof4Timepoint: Measure preoperative serum magnesium levels—

Countries

India

Contacts

Public ContactDr Sonali Gupta

Department of anaesthesiology, rgcirc

ek_mamta@yahoo.co.in09958443332

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026